Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: April 2015

Governor Christie Signs Legislation to Bolster Efforts to Fight Drug Abuse and Addiction

Trenton, NJ, April 30, 2015 ― Taking action to support New Jerseyans and their families faced with the disease of addiction, Governor Chris Christie yesterday signed legislative measures to enhance the State’s Project Medicine Drop program and to strengthen the Attorney General’s law enforcement coordination efforts against opioid drug abuse.

“I’m proud of what we’ve done in New Jersey and proud of the work that we continue to do together to help people reclaim their lives. But we cannot become complacent,” said Governor Christie.   Continue reading

Bipartisan Leaders Release House’s ‘21st Century Cures’ Discussion Draft as Legislative Process Continues

Washington, DC, April 29, 2015 ― After nearly a year of listening to patients, innovators, researchers, providers, consumers, and regulators, bipartisan Energy and Commerce Committee leaders today released a discussion draft marking continued progress in the 21st Century Cures initiative.

On Thursday — exactly one year to the day since full Committee Chairman Fred Upton (R-MI) and Rep. Diana DeGette (D-CO) launched the initiative — the Subcommittee on Health will hold a legislative hearing to review the draft.  Continue reading

President Proposes that Medicare Be Given Right to Negotiate the Cost of Drugs

Washington, DC, April 28, 2015 ― Robert Pear reports in The New York Times that, embedded in President Obama’s budget request to Congress is a paradox.  He proposes a major new initiative to develop drugs tailored to the genetic characteristics of individual patients, but he expresses deep concern about the costs of such specialty medicines for consumers and for the Medicare program.

President Obama has asked Congress to let Medicare officials negotiate prices with drug manufacturers — a practice explicitly forbidden by current law. Continue reading

MIT Study Faults U.S. for Risking Nation’s Innovation, R&D Edge

Washington, DC, April 28, 2015 ― Robert McMillan reports in The Wall Street Journal that, with Asia emerging as the world’s powerhouse of research and development (R&D), the United States risks losing its position as a magnet for the world’s best academic researchers, according to a report by the Massachusetts Institute of Technology.

The MIT authors warned that the U.S. government was spending an ever-smaller percentage of its budget on basic R&D.  Though the U.S. leads the world in total R&D outlays, Europe and Asia have been raising their government investment.

The report, titled “The Future Postponed: Why Declining Investment in Basic Research Threatens a U.S. Innovation Deficit,” lays out the funding challenges for research in 15 areas, including the life science areas of Alzheimer’s disease, infectious diseases and synthetic biology. Continue reading

Rutgers Molecular Genetics Professor Joachim Messing Elected to National Academy of Sciences

New Brunswick, NJ, April 28, 2015 ― Joachim Messing, director of Rutgers University’s Waksman Institute of Microbiology, has been selected to membership in the National Academy of Sciences, one of the highest honors an American scientist or engineer can achieve.

Dr. Messing, who is considered to be among the world’s top experts in molecular genetics, was among 84 new members elected and recognized this year for their distinguished and continuing achievements in original research. Continue reading

NIH Names Dr. Eliseo Pérez-Stable Director of National Institute on Minority Health and Health Disparities

Bethesda, MD, April 28, 2015 ― National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced today the selection of Eliseo J. Pérez-Stable, M.D., as Director of the National Institute on Minority Health and Health Disparities (NIMHD).  Dr. Pérez-Stable is expected to join NIH in September.

“Eliseo is a highly respected leader with rich experience in advancing efforts to eliminate health disparities,” said Dr. Collins. “He has the passion and vision to guide the NIMHD research agenda in this critically important area.” Continue reading

Former Congressman Rush Holt Elected to Group Seeking More Money for Health Research

Washington, DC, April 27, 2015 ―  The Star-Ledger reports that the Honorable Rush Holt, the former eight-term Congressman from New Jersey’s 12th District, has been elected to the board of directors of Research!America, a group that pushes for more research on improving the nation’s health.

Holt, a physicist by training, now serves as CEO of the American Association for the Advancement of Science and executive publisher of the Science family of academic journals.  Continue reading

Five Life Sciences Companies with NJ Connections Named to ‘Top 50 Companies for Diversity’ 2015 List

Somerset, NJ, April 27, 2015 NJBIZ has reported that DiversityInc announced the results of its annual Top 50 Companies for Diversity, and eight New Jersey companies made the Top 50.

Five life sciences companies — all members of the HealthCare Institute of New Jersey (HINJ), which is the voice of New Jersey’s life sciences community — were included on the 2015 list, including Novartis Pharmaceuticals Corporation, which ranked No. 1 for the second consecutive year.  Continue reading

U.S. House Kicks Off Legislative Phase of ‘21st Century Cures’ Initiative

Washington, DC, April 24, 2015 ― The U.S. House of Representatives Committee on Energy and Commerce yesterday announced that, after nearly a year of listening to patients, innovators, researchers, providers and regulators, 21st Century Cures next week will take the next step in the legislative phase with a hearing.

The hearing — “Legislative Hearing on 21st Century Cures” — will take place on Thursday, April 30 at 10:00 a.m. in room 2123 of the Rayburn House Office Building in Washington, DC. Continue reading

NJ Congressional Delegation Makes Top 10 in Roll Call ‘Clout Index’

Washington, DC, April 23, 2015 ― It has been a good while since folks back home in New Jersey focused on the “clout” of the New Jersey Congressional Delegation, and names like Torch, Rodino, Howard, Gallo and Roe would have been featured on that list.

Today, Roll Call confirmed something we have known for a good while: The New Jersey Congressional Delegation has gained significantly in seniority and on powerhouse committees.

Since 1990, Roll Call has been tracking the potential influence each state has on national affairs.  Each state’s delegation is scored using a weighted formula including total size, seniority, percentage from the party in power, chairmen and ranking members, and assignments to exclusive committees.

In the 2015 Clout Index, the New Jersey Congressional Delegation has gained significantly in seniority and on powerhouse committees, making the state number nine on the list. Continue reading